Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat
Completed · Phase 1
Conditions studied: Hypertension
In brief
This was a Phase 1, open-label, single dose study in healthy male subjects. The goals of this clinical trial were to determine how baxdrostat might be absorbed and metabolized using radioactive \[14C\] labeled baxdrostat. Subjects were administered a single oral dose of 10 mg containing approximately 100 μCi of \[14C\] baxdrostat. Subjects were to be confined to the study site for 9 to 15 days for blood, urine, and feces collections.
Key facts
- Study ID
- NCT05961384
- Run by
- AstraZeneca
- People needed
- 8
- Starts
- 2021-11-18
- Expected to finish
- 2022-01-15
- Last updated by the study team
- 2023-08-15
Who can join
Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.
Where it is running
- Labcorp Clinical Research Unit — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.